Therapeutic Solutions International, Inc. (TSOI) announced the granting of a patent covering the ability of QuadraMune and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers.
Therapeutic Solutions International, Inc.
Equities
TSOI
US8833781011
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | -0.14% | +16.67% | -30.00% |
1st Jan change | Capi. | |
---|---|---|
-30.00% | 3.21M | |
+10.11% | 126B | |
-6.21% | 11.33B | |
+6.07% | 9.27B | |
+37.46% | 5.5B | |
-23.66% | 4.61B | |
+8.53% | 3.45B | |
-8.69% | 2.81B | |
-10.91% | 2.09B | |
-6.38% | 2.08B |
- Stock Market
- Equities
- TSOI Stock
- News Therapeutic Solutions International, Inc.
- Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients